Insilico Medicine, the Hong Kong–listed AI drug discovery company, has signed a partnership with Korea’s SK Biopharmaceuticals to help develop new drugs for neuroimmune conditions in a deal valued at more than $2.5 billion.
Insilico will use its Pharma.AI platform to help design new candidates for neuroimmune treatments, while SK Biopharmaceuticals will then steer the late-stage development and commercialization of discovered treatments. While Insilico is expected to get $18 million in payments in the near-term, the deal could bring in up to $2.5 billion if the firm reaches certain development and commercial milestones, in addition to royalties.
